166 related articles for article (PubMed ID: 10573085)
1. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
Rebello PR; Hale G; Friend PJ; Cobbold SP; Waldmann H
Transplantation; 1999 Nov; 68(9):1417-20. PubMed ID: 10573085
[TBL] [Abstract][Full Text] [Related]
2. Campath-1H in renal transplantation: The University of Wisconsin experience.
Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
[TBL] [Abstract][Full Text] [Related]
3. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
4. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
6. Campath-1H use in pediatric renal transplantation.
Bartosh SM; Knechtle SJ; Sollinger HW
Am J Transplant; 2005 Jun; 5(6):1569-73. PubMed ID: 15888071
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
Reams BD; Davis RD; Curl J; Palmer SM
Transplantation; 2002 Sep; 74(6):903-4. PubMed ID: 12364881
[No Abstract] [Full Text] [Related]
8. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
Magliocca JF; Knechtle SJ
Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
[TBL] [Abstract][Full Text] [Related]
9. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy.
Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Norfolk ER; Blasick TM; Lun M; Brown RE; Hartle JE; Potdar S
Am J Transplant; 2005 Mar; 5(3):604-7. PubMed ID: 15707416
[TBL] [Abstract][Full Text] [Related]
10. Campath-1G. Campath IgG, Campath-1-IgG antibody.
Drugs R D; 1999 Jan; 1(1):71-2. PubMed ID: 10565991
[No Abstract] [Full Text] [Related]
11. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
12. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Skaletsky M; Norfolk ER; Brown RE; Hartle JE; Potdar S
Ann Clin Lab Sci; 2004; 34(2):209-13. PubMed ID: 15228236
[TBL] [Abstract][Full Text] [Related]
13. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.
Cai J; Terasaki PI; Bloom DD; Torrealba JR; Friedl A; Sollinger HW; Knechtle SJ
Transplantation; 2004 Sep; 78(6):919-24. PubMed ID: 15385814
[TBL] [Abstract][Full Text] [Related]
14. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
16. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.
Knechtle SJ; Pirsch JD; H Fechner J; Becker BN; Friedl A; Colvin RB; Lebeck LK; Chin LT; Becker YT; Odorico JS; D'Alessandro AM; Kalayoglu M; Hamawy MM; Hu H; Bloom DD; Sollinger HW
Am J Transplant; 2003 Jun; 3(6):722-30. PubMed ID: 12780564
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
19. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
[TBL] [Abstract][Full Text] [Related]
20. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
James LC; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1999 Jun; 289(2):293-301. PubMed ID: 10366506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
